Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in FranceResearch in context
Summary: Background: To evaluate the acceptance and safety of the treatment of newborns with nirsevimab (a long-acting monoclonal antibody designed to prevent respiratory syncytial virus infections) during the first season of implementation. Methods: A longitudinal, prospective, single-centre cohor...
Saved in:
| Main Authors: | Charlotte Ocana de Sentuary, Clara Testard, Marion Lagrée, Maxime Leroy, Lisa Gasnier, Alicia Enes-Dias, Constance Leruste, Diariatou Diallo, Michael Génin, Thameur Rakza, François Dubos |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | EClinicalMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537024005650 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Administration of Nirsevimab for RSV Prophylaxis in Infants: A Comprehensive Review
by: Pan-Pan Wu, et al.
Published: (2025-04-01) -
Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain
by: Jaime Jesús Pérez Martín, et al.
Published: (2024-12-01) -
Effectiveness of nirsevimab immunization against RSV infection in preterm infants: a systematic review and meta-analysis
by: Xiaopeng Wang, et al.
Published: (2025-04-01) -
Optimal implementation of an Ontario nirsevimab program for respiratory syncytial virus (RSV) prophylaxis: Recommendations from a provincial RSV expert panel
by: Bosco Paes, et al.
Published: (2024-12-01) -
Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis from Spain’s 2023–2024 RSV Immunisation Campaign
by: Pablo Estrella-Porter, et al.
Published: (2025-06-01)